Pacific Biosciences of California (NASDAQ:PACB) Issues Earnings Results

Pacific Biosciences of California (NASDAQ:PACB) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01), FiscalAI reports. Pacific Biosciences of California had a negative net margin of 80.35% and a negative return on equity of 571.06%. The firm had revenue of $39.01 million for the quarter, compared to analysts’ expectations of $42.90 million.

Here are the key takeaways from Pacific Biosciences of California’s conference call:

• Leadership transition: Christian Henry stepped down as CEO and will remain on PacBio’s board as an advisor, with Mark Van Oene taking over immediately and prioritizing clinical-market expansion, SMRT Next adoption, and leaner execution.
• SMRT Next momentum is encouraging, with more than one-third of the installed base enabling the new software in June. PacBio expects the multi-use chemistry, which lowers the listed cost of a 20x HiFi genome by 30%, to drive higher throughput, larger population-scale projects, and improved utilization over time.
• Second-quarter revenue was $39 million, roughly flat year over year, while Vega placements declined to 26 from 38 amid academic and government funding constraints. PacBio lowered its 2026 revenue outlook to $155 million–$165 million and expects consumables pull-through of only $200,000–$225,000 per Revio system.
• Non-GAAP gross margin fell to 36% due to compute and memory costs, lower manufacturing volumes, and $1.1 million of Vega manufacturing-transition expenses. The company now expects 2026 gross margin of 35%–37% and cash-flow breakeven in 2028, a year later than previously anticipated, despite planned restructuring savings.
• Clinical adoption continues to strengthen, particularly in EMEA, where revenue grew 52% year over year and clinical consumables shipments rose 67% globally. Recent publications supporting HiFi sequencing for rare-disease diagnostics and other clinical applications could help accelerate payer and health-system adoption.

Pacific Biosciences of California Trading Down 10.4%

Pacific Biosciences of California stock traded down $0.14 during mid-day trading on Thursday, hitting $1.17. The company had a trading volume of 14,451,182 shares, compared to its average volume of 6,624,359. Pacific Biosciences of California has a 12 month low of $1.09 and a 12 month high of $2.73. The company has a market capitalization of $361.85 million, a PE ratio of -2.71 and a beta of 2.31. The stock’s 50 day moving average price is $1.47 and its two-hundred day moving average price is $1.56.

Pacific Biosciences of California News Roundup

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: PacBio introduced upgraded Vega SPRQ-Nx chemistry, promising up to 90 gigabases of HiFi data per run, 40% lower cost per gigabase, faster workflows, and new compliance controls. The enhancements could support customer adoption and consumables growth. PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system
• Neutral Sentiment: Mark Van Oene was appointed president and chief executive officer, replacing Christian Henry after six years. The leadership change could accelerate a leaner operating structure and commercialization efforts, but it also introduces execution uncertainty. PacBio Appoints Mark Van Oene as President and Chief Executive Officer
• Negative Sentiment: Second-quarter revenue was approximately $39.0 million, below the roughly $42.9 million analyst estimate, with sales down 2%. Growth in consumables and Europe, the Middle East and Africa was insufficient to offset weaker instrument sales and weakness in Asia-Pacific. The quarterly loss was about $0.14 per share, roughly in line with or slightly below estimates depending on the source. PacBio Announces Second Quarter 2026 Financial Results
• Negative Sentiment: Management cut its 2026 revenue forecast to $155 million-$165 million, below the approximately $167.4 million consensus estimate. Analysts are also highlighting persistent operating losses, cash of less than $237 million, and nearly $645 million of debt, increasing concerns about liquidity and the pace of a potential turnaround. PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut

Wall Street Analyst Weigh In

PACB has been the subject of several research reports. Barclays increased their price target on shares of Pacific Biosciences of California from $1.00 to $1.50 and gave the stock an “underweight” rating in a research note on Monday, May 11th. Zacks Research lowered shares of Pacific Biosciences of California from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 20th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Pacific Biosciences of California in a report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $1.83.

Hedge Funds Weigh In On Pacific Biosciences of California

Several large investors have recently modified their holdings of the stock. Intech Investment Management LLC lifted its stake in shares of Pacific Biosciences of California by 5.2% in the 3rd quarter. Intech Investment Management LLC now owns 132,368 shares of the biotechnology company’s stock worth $169,000 after purchasing an additional 6,564 shares during the period. Mercer Global Advisors Inc. ADV boosted its holdings in shares of Pacific Biosciences of California by 47.9% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 20,663 shares of the biotechnology company’s stock worth $39,000 after buying an additional 6,695 shares during the last quarter. Cetera Investment Advisers grew its position in Pacific Biosciences of California by 10.1% during the second quarter. Cetera Investment Advisers now owns 104,725 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 9,617 shares during the period. Raymond James Financial Inc. grew its position in Pacific Biosciences of California by 6.5% during the third quarter. Raymond James Financial Inc. now owns 161,865 shares of the biotechnology company’s stock valued at $207,000 after buying an additional 9,896 shares during the period. Finally, Deutsche Bank AG increased its holdings in Pacific Biosciences of California by 4.8% during the fourth quarter. Deutsche Bank AG now owns 218,981 shares of the biotechnology company’s stock valued at $409,000 after buying an additional 10,107 shares during the last quarter.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.